Loading
Yanuki
KEYWORD TOPIC
Dupilumab Shows Promise for Atopic Dermatitis in Skin of Color | Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials | Regeneron to Acquire 23andMe for $256 Million | Dupilumab Shows Promise for Atopic Dermatitis in Skin of Color | Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials | Regeneron to Acquire 23andMe for $256 Million

Health / Dermatology

Dupilumab Shows Promise for Atopic Dermatitis in Skin of Color

A recent Phase IV clinical trial, DISCOVER, has revealed promising results for Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in adolescents and adults with skin of color. The study, presented at the 2025 Revolut...

Regeneron and Sanofi’s dupilumab shows promise in AD trial
Dupilumab Shows Promise for Atopic Dermatitis in Skin of Color Image via Yahoo Finance
TOPIC regeneron

Pharma / Clinical Trials

Sanofi and Regeneron's Itepekimab Shows Mixed Results in COPD Trials

Sanofi and Regeneron's investigational drug, itepekimab, designed for chronic obstructive pulmonary disease (COPD), has yielded mixed outcomes in its Phase 3 clinical trials. While one study (AERIFY-1) achieved its primary endpoint, a paral...

Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials

Finance / Mergers & IPOs

Regeneron to Acquire 23andMe for $256 Million

Regeneron Pharmaceuticals is set to acquire 23andMe, the genetic testing firm, for $256 million. This acquisition, occurring through a bankruptcy auction, ensures 23andMe's mission continues with strong privacy protections for consumer data...

Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million